These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 29330751)

  • 1. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.
    Youland RS; Pafundi DH; Brinkmann DH; Lowe VJ; Morris JM; Kemp BJ; Hunt CH; Giannini C; Parney IF; Laack NN
    J Neurooncol; 2018 May; 137(3):583-591. PubMed ID: 29330751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.
    Pafundi DH; Laack NN; Youland RS; Parney IF; Lowe VJ; Giannini C; Kemp BJ; Grams MP; Morris JM; Hoover JM; Hu LS; Sarkaria JN; Brinkmann DH
    Neuro Oncol; 2013 Aug; 15(8):1058-67. PubMed ID: 23460322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
    J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our Experience.
    Evangelista L; Cuppari L; Bellu L; Bertin D; Caccese M; Reccia P; Zagonel V; Lombardi G
    Curr Radiopharm; 2019; 12(3):220-228. PubMed ID: 30644351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
    Bashir A; Brennum J; Broholm H; Law I
    J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of fusion of metabolic and structural images for stereotactic biopsy of brain tumors without enhancement after contrast medium injection.
    Todeschi J; Bund C; Cebula H; Chibbaro S; Lhermitte B; Pin Y; Lefebvre F; Namer IJ; Proust F
    Neurochirurgie; 2019 Dec; 65(6):357-364. PubMed ID: 31560911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 13N-Ammonia PET/CT for detection of recurrent glioma: a prospective comparison with contrast-enhanced MRI.
    Khangembam BC; Sharma P; Karunanithi S; Singhal A; Das CJ; Kumar P; Julka PK; Bandopadhyaya GP; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2013 Nov; 34(11):1046-54. PubMed ID: 24025920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial results of a phase II trial of
    Breen WG; Youland RS; Giri S; Jacobson SB; Pafundi DH; Brown PD; Hunt CH; Mahajan A; Ruff MW; Kizilbash SH; Uhm JH; Routman DM; Jones JE; Brinkmann DH; Laack NN
    J Neurooncol; 2022 Jul; 158(3):323-330. PubMed ID: 35583721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of multiparametric 18F-fluoro-L-3,4-dihydroxy-phenylalanine PET/MRI in post-therapy assessment of patients with gliomas.
    Fraioli F; Shankar A; Hyare H; Ferrazzoli V; Militano V; Samandouras G; Mankad K; Solda F; Zaccagna F; Mehdi E; Lyasheva M; Bomanji J; Novruzov F
    Nucl Med Commun; 2020 Jun; 41(6):517-525. PubMed ID: 32282634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma.
    Karunanithi S; Sharma P; Kumar A; Khangembam BC; Bandopadhyaya GP; Kumar R; Goenka A; Gupta DK; Malhotra A; Bal C
    Eur Radiol; 2013 Sep; 23(9):2628-35. PubMed ID: 23624623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement.
    Ideguchi M; Nishizaki T; Ikeda N; Okamura T; Tanaka Y; Fujii N; Ohno M; Shimabukuro T; Kimura T; Ikeda E; Suga K
    J Neurooncol; 2018 Jul; 138(3):537-548. PubMed ID: 29516344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET.
    Morana G; Piccardo A; Tortora D; Puntoni M; Severino M; Nozza P; Ravegnani M; Consales A; Mascelli S; Raso A; Cabria M; Verrico A; Milanaccio C; Rossi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2084-2093. PubMed ID: 28752225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
    Verburg N; Koopman T; Yaqub MM; Hoekstra OS; Lammertsma AA; Barkhof F; Pouwels PJW; Reijneveld JC; Heimans JJ; Rozemuller AJM; Bruynzeel AME; Lagerwaard F; Vandertop WP; Boellaard R; Wesseling P; de Witt Hamer PC
    Neuro Oncol; 2020 Mar; 22(3):412-422. PubMed ID: 31550353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effects of 18F-FDG PET-CT and MRI in identifying and grading gliomas.
    Song PJ; Lu QY; Li MY; Li X; Shen F
    J Biol Regul Homeost Agents; 2016; 30(3):833-838. PubMed ID: 27655507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
    Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.